Oculis Details Positive Stage 1 Results from Phase 3 Trial for Diabetic Macular Edema

 Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that the positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME), will be presented as a late-breaking abstract at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting, taking place Friday, November 3, 2023 through Monday, November 6, 2023 in San Francisco, California.

https://www.globenewswire.com/news-release/2023/11/01/2770923/0/en/Oculis-to-Present-a-Late-Breaking-Abstract-at-the-American-Academy-of-Ophthalmology-2023-Annual-Meeting-on-the-Positive-Stage-1-Results-from-Phase-3-DIAMOND-Trial-for-Diabetic-Macu.html